Comparison of the efficacy of INISYNC combination tablets and EquMet combination tablets LD on glycemic control in type 2 diabetic patients: A multicenter, open-label, randomized, parallel group, comparative trial. - Comparison of the efficacy of INISYNC combination tablets and EquMet combination tablets LD on glycemic control in type 2 diabetic patients: A multicenter, open-label, randomized, parallel group, comparative trial.

Asahikawa Medical University0 个研究点目标入组 61 人开始时间: 2018年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Contraindications to alogliptin, vildagliptin, and metformin 2)Diabetic patients with type 1 diabetes and other causes 3)Diabetic ketoacidosis 4)Patients with a history of severe hypoglycemia with coma or loss of consciousness 5)Severe infection, severe trauma 6)Patients with poorly controlled hypertension despite drug treatment 7)Severe renal, hepatic and heart disease 8)Proliferative retinopathy 9)Patients with a history of malignant tumors 10)Not suitable for participate in this study from serious complications judged by a doctor 11)Women with the potential to become pregnant or pregnant, and lactating women 12)Patients judged by doctors to be inappropriate for participation in this study

发起方